中国医药
中國醫藥
중국의약
CHINA MEDICINE
2015年
2期
165-169
,共5页
楼君%盛誉%吴闵丽%汤婉芬
樓君%盛譽%吳閔麗%湯婉芬
루군%성예%오민려%탕완분
人源核苷酸平衡转运体1%非小细胞肺癌,晚期%吉西他滨%长春瑞滨
人源覈苷痠平衡轉運體1%非小細胞肺癌,晚期%吉西他濱%長春瑞濱
인원핵감산평형전운체1%비소세포폐암,만기%길서타빈%장춘서빈
Human equilibrative nucleoside transporter 1%Non-small-cell carcinoma,advanced%Gemcitabine%Vinorelbine
目的 评价非细小细胞肺癌(NSCLC)患者术后人源核苷酸平衡转运体1(hENT1)蛋白表达水平与吉西他滨化疗敏感度的相关性.方法 筛选2007-2011年浙江金华广福医院肿瘤内科收治的经病理确诊为NSCLC并行手术切除后患者47例,完全随机分为GP组和NP组,GP组23例选用吉西他滨联合顺铂化疗,顺铂80 mg/m2,第1～3天静脉滴注,吉西他滨800 ～1 250 mg/m2,第1、8天使用;NP组24例选用长春瑞滨联合顺铂化疗,顺铂用法同前,长春瑞滨25 mg/m2,第1、8天使用.对47例患者手术切除肺癌组织蜡块标本采用免疫组织化学链霉菌抗生物素蛋白-过氧化物酶连结法检测hENT1蛋白表达水平.术后实施2周期以上吉西他滨或长春瑞滨化疗,随访患者的生存期,评价hENT1蛋白表达水平与2种化疗方案疗效相关性.结果 GP组hENT1高表达患者13例,无进展生存期为(28±18)个月,中位无进展生存期32个月;NP组hENT1高表达患者14例,无进展生存期为(24±16)个月,中位无进展生存期22个月,差异均有统计学意义(P =0.042,P=0.037).GP组hENT1低表达患者(10例)中位总生存期35个月,NP组hENT1低表达患者(10例)中位总生存期34个月比较,差异无统计学意义(P＞0.05).结论 对于NSCLC患者,hENT1蛋白表达程度与吉西他滨的化疗敏感性相关.
目的 評價非細小細胞肺癌(NSCLC)患者術後人源覈苷痠平衡轉運體1(hENT1)蛋白錶達水平與吉西他濱化療敏感度的相關性.方法 篩選2007-2011年浙江金華廣福醫院腫瘤內科收治的經病理確診為NSCLC併行手術切除後患者47例,完全隨機分為GP組和NP組,GP組23例選用吉西他濱聯閤順鉑化療,順鉑80 mg/m2,第1～3天靜脈滴註,吉西他濱800 ～1 250 mg/m2,第1、8天使用;NP組24例選用長春瑞濱聯閤順鉑化療,順鉑用法同前,長春瑞濱25 mg/m2,第1、8天使用.對47例患者手術切除肺癌組織蠟塊標本採用免疫組織化學鏈黴菌抗生物素蛋白-過氧化物酶連結法檢測hENT1蛋白錶達水平.術後實施2週期以上吉西他濱或長春瑞濱化療,隨訪患者的生存期,評價hENT1蛋白錶達水平與2種化療方案療效相關性.結果 GP組hENT1高錶達患者13例,無進展生存期為(28±18)箇月,中位無進展生存期32箇月;NP組hENT1高錶達患者14例,無進展生存期為(24±16)箇月,中位無進展生存期22箇月,差異均有統計學意義(P =0.042,P=0.037).GP組hENT1低錶達患者(10例)中位總生存期35箇月,NP組hENT1低錶達患者(10例)中位總生存期34箇月比較,差異無統計學意義(P＞0.05).結論 對于NSCLC患者,hENT1蛋白錶達程度與吉西他濱的化療敏感性相關.
목적 평개비세소세포폐암(NSCLC)환자술후인원핵감산평형전운체1(hENT1)단백표체수평여길서타빈화료민감도적상관성.방법 사선2007-2011년절강금화엄복의원종류내과수치적경병리학진위NSCLC병행수술절제후환자47례,완전수궤분위GP조화NP조,GP조23례선용길서타빈연합순박화료,순박80 mg/m2,제1～3천정맥적주,길서타빈800 ～1 250 mg/m2,제1、8천사용;NP조24례선용장춘서빈연합순박화료,순박용법동전,장춘서빈25 mg/m2,제1、8천사용.대47례환자수술절제폐암조직사괴표본채용면역조직화학련매균항생물소단백-과양화물매련결법검측hENT1단백표체수평.술후실시2주기이상길서타빈혹장춘서빈화료,수방환자적생존기,평개hENT1단백표체수평여2충화료방안료효상관성.결과 GP조hENT1고표체환자13례,무진전생존기위(28±18)개월,중위무진전생존기32개월;NP조hENT1고표체환자14례,무진전생존기위(24±16)개월,중위무진전생존기22개월,차이균유통계학의의(P =0.042,P=0.037).GP조hENT1저표체환자(10례)중위총생존기35개월,NP조hENT1저표체환자(10례)중위총생존기34개월비교,차이무통계학의의(P＞0.05).결론 대우NSCLC환자,hENT1단백표체정도여길서타빈적화료민감성상관.
Objective To evaluate the relevance between the gemcitabine chemotherapy sensitivity and the expression level of human equilibrative nucleoside transporter 1 (hENT1) after non-small-cell carcinoma (NSCLC) operation.Methods A total of 47 NSCLC patients were divided into GP group (23 patients) and NP group (24 patients) by random digit grouping method.GP group received gemcitabine and cisplatin chemotherapy.Cisplatin was used intravenously at the dose of 80 mg/m2 from the 1st to 3rd days and gemcitabine was used intravenously at the dose of 800 to 1 250 mg/m2 on the 1st and 8th day.NP group received gemcitabine and cisplatin chemotherapy.Cisplatin was used intravenously as above and vinorelbine was used intravenously at the dose of 25 mg/m2 on the 1st and 8th day.The expression level of hENT1 in lung cancer paraffin block specimens of the 47 NSCLC patients after operation was tested by immunohistochemical SP method; more than 2 cycles' chemotherapy were implemented by Gemcitabine and vinorelbine.The patients' life cycles were followed up and the relevance among gemcitabine chemotherapy sensitivity and the hENT1 expression level were evaluated.Results progressionfree survival of hENT1 high expression was (28 ± 18) months in GP group,(24 ± 16) months in the NP group,the differences between the two groups was significant (P =0.042),high expression median progression-free survival was 32 months in the GP group,and 22 months in the NP group,the difference between both groups was significant (P =0.037).GP group had a median survival of 35 months after chemotherapy in the low expression of hENT1,while NP group had a median survival of 34 months after chemotherapy in the low expression of hENT1 ; the two groups had no significant difference (P ＞ 0.05).Conclusions Degree of hENT1 expression associated with the chemosensitivity of gemcitabine.It may become a new target of gemcitabine chemotherapy for NSCLC.
